Portola Anticipates “Best In Class” Status For Novel Phase II Anticoagulant
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held biotech cites betrixaban’s potential for daily dosing and safety in renally-impaired patients as differentiation points from other candidates.